Figure 2.
Anti-EGFR immunostaining pattern in HT-29 and Caco-2 cell lines, respectively. a, b (untreated); c, d (10 nM EGF treated); e, f (5 nmol/L cetuximab treated); g, h (5 nmol/L cetuximab plus 10 nM EGF treated).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.